Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Arlington Asset Investment Corp. Issues Letter Urging Shareholders To Protect Their Dividend And Investment
-
Maxim Group Starts Shopify (SHOP) at Hold
-
Maxim Group Downgrades Oxford Lane (OXLC) to Sell
-
Maxim Group Starts Wayfair (W) at Buy
-
Maxim Group Starts Overstock.com (OSTK) at Buy
-
Maxim Group Starts Etsy (ETSY) at Buy
-
Opexa (OPXA) SPMS Data in September Could Signal The First Therapy in a $7B Mkt - Maxim
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Maxim Group Upgrades Fifth Street Finance (FSC) to Hold
-
Maxim Group Starts Viking Therapeutic (VKTX) at Buy
-
Maxim Group Starts CytoSorbents (CTSO) at Buy
-
OpGen Announces Closing of $10 Million Private Placement
-
AssuredPartners Acquires MaximGroup
-
Vivint Smart Home to Keynote Parks Associates' 20th Annual CONNECTIONS(TM) Conference
-
Notable Analyst Rating Changes 5/17: (HAL) (CFX) (FCX) Upgraded; (HIG) (GST) (ANAC) Downgraded
-
Maxim Group Starts Bob Evans Farms (BOBE) at Buy
-
NAPCO Security Bolsters its Investor Relations Efforts
-
Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering
-
Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Moves Closer to Human Trials
-
Prima Biomed (PBMD) PT Raised to $5 at Maxim Group Amid CVac Partnership
-
Maxim Group Bullish on Galena Biopharma (GALE) Into Interim Analysis of PRESENT Study
-
IsoRay (ISR) in a Strong Position to Execute on Cesium-131 - Maxim Group
-
Notable Analyst Rating Changes 5/6: (ARIA) (MAC) (GM) Upgraded; (FRT) (WMB) (ZTS) Downgraded
-
Maxim Group Starts ContraVir Pharma (CTRV) at Buy
-
Medivation (MDVN) PT Raised to $76 at Maxim Group with Shares 'In Play'
-
ADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Parks Associates: 27% of U.S. Car Owners Want Their Car to Be Able to Connect to Their Smart Home Devices
-
Maxim Group Upgrades Intevac (IVAC) to Buy
-
Viking Therapeutics Announces Full Exercise of Over-Allotment Option
-
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
-
ADMA Biologics (ADMA) Prices 1.89M Common Stock Offering at $6.50/Share
-
ADMA Biologics Announces Pricing of Public Offering of Common Stock
-
Chipotle Mexican Grill's (CMG) Price Target Lowered to $300 at Maxim
-
CORRECTING and REPLACING The Vatican Hosts Third International Regenerative Medicine Conference
-
The Vatican Hosts Third International Regenerative Medicine Conference
-
Chipotle's troubles might help Panera as both serve up reports
-
Streetinsider.com's Hot Lunchtime Reads 4/25: (RLYP) (P) (AVXL) (PRGO)
-
Maxim Group Weighs in on Anavex Life Sciences (AVXL) Following Positive Anecdotal Aussie News Story
-
Jensyn Acquisition Corp. Announces Termination of Over-Allotment Option and Common Stock, Rights and Warrants to Commence Separate Trading on or about April 25, 2016
-
Prima BioMed Ltd (PBMD) Adds to Early Gains
-
Streetinsider.com's Hot Lunchtime Reads 4/20: (NVS) (BLUE) (MSFT) (DISH)
-
bluebird bio (BLU) Bullish View Reiterated at Maxim Group as Lenti-D Continues to Show Signs of Efficacy in CCALD
-
Maxim Group Reiterates Positive View on Oculus Innovative (OCLS) Following 510(k) Clearance
-
Maxim Group Starts QCR Holdings (QCRH) at Buy
-
Over 100 Companies Speaking at Parks Associates' 20th-Annual CONNECTIONS: The Premier Connected Home Conference, May 24-26 in San Francisco
-
Maxim Group Starts Prima Biomed (PBMD) at Buy, $4 PT
-
The PIPEs Report Sees Small-Cap Equity Financing Growth at the End of Q1 2016
-
Maxim Group LLC Expands Equity Research With the Appointment of a Consumer Analyst
-
Maxim Group Starts BioPharmX Corp (BPMX) at Buy

